Biotech Is the Rate-Cut Trade in Disguise

A week ago I wrote that leadership had left the mega-cap “generals” and split into two baskets, semiconductors (velocity) and regional banks (breadth). That’s still true. But the dashboard has been quietly flagging a third group climbing the leaderboard, and this week it’s undeniable: biotech is now the deepest pocket of leadership in the entire Nasdaq.

Of the stocks that currently clear a strict leadership bar — top-decile relative strength, in a confirmed uptrend, liquid, sitting at new highs — 30% are biotech or healthcare. No other group is close. And it isn’t a handful of lottery tickets dragging the average: it’s a broad, accelerating cohort.

What the data actually shows

Confirmed and extending: Absci (+272% over 3 months), Nuvectis (+247%), Definium (+134%), Twist Bioscience (+113%), Sellas (+150%), Travere (+112%) — all making fresh highs, not fading.
Freshly igniting (the most interesting part — these broke out this week): MBX Biosciences (+65% in a month), Apogee (+60%), Tango (+55%), Oruka (+53%), 10x Genomics (+48%), AbCellera (+38%), Relay (+30%). New leadership, not late-stage chasers.
Breadth, not noise: when a third of the entire market’s leaders come from one sector, and the new breakouts skew the same way, that’s a rotation with conviction — the kind that tends to persist longer than a single-name squeeze.

Why now and the part nobody’s connecting

Here’s the non-consensus piece. Everyone can see biotech is moving. Almost no one is naming why, and the why is macro: yields are falling and many of these are also AI plays. Over the past month bonds caught a bid, gold and commodities sold off, the dollar firmed, the disinflation/easing trade I’ve been tracking. Biotech is the purest long-duration equity there is: its value sits in cash flows a decade out, which get more valuable as the discount rate drops. Falling yields aren’t a side note to the biotech rally — they’re the fuel.

So this isn’t really a “biotech is hot” story. It’s the rate-cut trade wearing an AI lab coat. That reframing matters, because it tells you what would end it: if yields reverse higher, this is the group that unwinds first and hardest. The macro tailwind is the thesis and the risk in one.

Grading last week’s call

I try to grade myself, because a forecast you never check is just an opinion. Earlier this week I singled out the diagnostics corner, NeoGenomics, CareDx, Personalis, as the highest-convexity setups: leaders sitting right at their breakout pivots, small defined risk, open upside. Two sessions later they’re up roughly 9–13%. I’m not posting that to take a victory lap, I’m posting it because the method (rank by relative strength, demand a tight setup, let the cross-section pick) did the work. Sometimes it won’t. The discipline is what compounds, not any single call.

The honest caveats

Biotech is the most headline-fragile sector there is, a single trial readout can halve a stock overnight, which is exactly why you play the basket, not the hero name. And this is a snapshot: a cross-section can rank the market, it can’t predict it. I don’t yet know whether these breakouts persist; I know they’re broad, accelerating, and macro-supported as of Friday’s close. I’m tracking the cohort daily to see if the breadth deepens or the leaders start failing.

Also remember that a shift in the Fed’s reaction function can destroy this trade in one afternoon. And Warsh is a Druckenmiller protege, who has said in prior occasions that the best way to manage interest rates is to “sneak one in” when the market is happy.

The read, as exposures

Leadership has a new third leg: biotech — broad (30% of leaders) and accelerating. Owning “growth” increasingly means owning this.
It’s a duration trade. The macro support is falling yields; that’s also the single thing to watch for the exit.
Genomics/diagnostics is the highest-quality slice — Twist, 10x, AbCellera, the diagnostics names — real revenue, not just clinical binaries.
Play the basket, not the binary. The convexity is in the group; the catastrophe risk is in the single name.

The cross-section nominated biotech before the headlines will. Whether it convicts is what the next few weeks of data will tell us.

Investment Gems